Bone Marrow Transplantation

Marrow Karyotype Has Pivotal Role in Predicting Outcome

Published in Blood Weekly, October 19th, 1998

Novel treatment strategies are needed to improve results with allogeneic bone marrow transplantation in patients with myelodysplastic syndrome, researchers indicated.

Treatment options for patients with myelodysplastic syndrome (MDS) are limited; allogeneic bone marrow transplantation (BMT) is the only proven curative therapy. While 30 percent to 50 percent of MDS patients who receive BMT experience long-term, event-free survival (EFS), relapse of disease and nonrelapse mortality (NRM) are significant.

To identify prognostic factors that influence outcome in this patient population, Thomas J. Nevill, Vancouver Hospital and Health Sciences Centre,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1998-10-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry